March 2026 SCRI Release Notes Copied
The following updates were completed between Feb. 20 – March 19, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 25061 | USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Eribulin Q21D – v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Gemcitabine + Carboplatin Q21D – v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Nab-Paclitaxel Q28D – v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Paclitaxel Q21D – v2.0 15Aug2025 USOR 25061 BRE 470 Phase 3 Pumitamig or Placebo + Paclitaxel Q28D – v2.0 15Aug2025 |
| 25087 | USOR 25087 BRE 471 Phase 1b GDC-4198 + Giredestrant Q28D – v2.0 04JUN2025 USOR 25087 BRE 471 Phase 1b GDC-4198 Q28D – v2.0 04JUN2025 USOR 25087 BRE 471 Phase 2 GDC-4198 + Giredestrant Q28D – v2.0 04JUN2025 USOR 25087 BRE 471 Phase 2 Giredestrant + Abemaciclib Q28D – v2.0 04JUN2025 |
| 25137 | USOR 25137 GYN 164 Phase 3 Bevacizumab maintenance Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Carboplatin + Pegylated Liposomal Doxorubicin + Bevacizumab Q28D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Gemcitabine + Carboplatin + Bevacizumab Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Gemcitabine Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 LY4170156 + Bevacizumab Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 LY4170156 Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Mirvetuximab Soravtansine Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Paclitaxel + Carboplatin + Bevacizumab Q21D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Paclitaxel Q28D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Pegylated Liposomal Doxorubicin Q28D – 31Oct2025 USOR 25137 GYN 164 Phase 3 Topotecan Q28D – 31Oct2025 |
| 25040 | USOR 25040 LUN 619 Phase 2 Exploratory Arm V940 + Docetaxel Q21D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction Pembrolizumab + Nab-paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction Pembrolizumab + Paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction V940 or Placebo + Pembrolizumab + Nab-paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Induction V940 or Placebo + Pembrolizumab + Paclitaxel + Carboplatin Q42D 11Jul2025 USOR 25040 LUN 619 Phase 2 Maintenance V940 or Placebo + Pembrolizumab Q42D 11Jul2025 |
| 25142 | USOR 25142 GU 298 Phase 3 Safety Lead-In Vepugratinib + Enfortumab vedotin-ejfv + Pembrolizumab Q21D – 01Aug2025 USOR 25142 GU 298 Phase 3 Vepugratinib or Placebo + Enfortumab vedotin-ejfv + Pembrolizumab Q21D – 01Aug2025 |
| 25175 | USOR 25175 GU 302 Phase 1b Cohort B Part 1 PF-08634404 + Enfortumab Vedotin Q21D – 26Jan2026 USOR 25175 GU 302 Phase 1b/2 Cohort A PF-08634404 Q21D – 26Jan2026 |
| 25065 | USOR 25065 LUN 623 Phase 3 Atezolizumab Q21D – v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Durvalumab Q28D – v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Nivolumab Q28D – v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Pembrolizumab Q21D – v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Zongertinib Q42D (C1-10) – v1.0 19JUN2025 USOR 25065 LUN 623 Phase 3 Zongertinib Q84D (C11-18) – v1.0 19JUN2025 |
| 25153 | USOR 25153 LUN 644 Phase 3 Pumitamig or Pembrolizumab Q21D – 09DEC2025 |
| 25152 | USOR 25152 LUN 643 Phase 3 Durvalumab Q28D – 09Dec2025 USOR 25152 LUN 643 Phase 3 Pumitamig Q21D – 09Dec2025 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Regimen Instructions | Other Changes |
| 22118 | Amendment 3 16APR2025 | Regimen Comments; Administration | Update drug; instructions |
| 22322 | PA Version J; 11th July 2025 | N/A | Update drug; instructions |
| 22332 | Version 3.0; 21 July 2025 | Regimen comments; admin | Update drug; instructions |
| 23031 | PA v6.0: 02 Dec 2025 | Regimen comments; admin | Update drug; instructions, premedication, New Arms |
| 23031 | PM v6.0; 20th January 2026 | N/A | Update Drug; instructions |
| 23041 | Version 8.0; 03 November 2025 | Regimen Comments; prophylaxis | Update drug; instructions |
| 23244 | Protocol Amendment V 3.0, 04DEC2024, Clarification letter for protocol v2.0, Protocol amendment v2.0 | N/A | Update drug; admin/prep |
| 23245 | PA 03: 04 Sep 2025 | N/A | Update drug; instructions, procurement.
Added drug |
| 23292 | Protocol v20.0; 12th November 2025 | Regimen comments; admin | N/A |
| 24005 | PA v3.0: 13 Sept 2024 | N/A | Update drug; admin/prep, Name |
| 24021 | PA v2.0; 25th June 2025 | Regimen Comments; admin, premedication | Update drug; instructions, predmedication, frequency.
Added drug |
| 24110 | PM v5.0; 9th February 2026 | N/A | Update drug; instructions |
| 24110 | PM Pembrolizumab v3.0; 9-February-2026 | N/A | Update Drug Instructions |
| 24157 | PM v4.0: 19 Nov 2025 | N/A | Update drug; instructions |
| 24168 | Amendment 7.0/US-1, v1.0; 10 March 2025 | Regimen comments; prophylaxis, observation | Update drug; instructions, premedication, dose/form |
| 24170 | PM v5.0; 04 November 2025 | N/A | Update drug; dose/form |
| 24170 | Version 2.0; 04 November 2025 | Regimen Comments; administration | Update drug; dose/form, instructions |
| 24321 | Version 1.0; 26 Sept 2025 | Regimen comments; prophylaxis | Update drug; instructions, premedication |
| 24325 | PM v.3.0; 3rd February 2026 | N/A | Update drug; procurement |
| 24333 | IP Procurement Update | N/A | Update drug; procurement |
| 25049 | PM v2.0; 2-March-2026 | N/A | Update drug; instructions |
| 23297 | Memo; 27 August 2025 | N/A | New Arms |
| 24270 | PM v6: 19 Dec 2025 | N/A | Update Drug; admin/prep |
| 24155 | PM v5.0; 6th October 2025 | N/A | Update drug; admin/prep |
| 24203 | PA01: 10 Sep 2025 | Regimen Comments; administration, premedication | Update drug; instructions |
| 24266 | Protocol v2.0; 5-December-2025 | Regimen Comments; premedication | New Arms.
Update Drug; instructions |
| 25031 | Protocol v2.0; 5-December-2025 | N/A | Update drug; admin/prep |
| 24293 | Procurement change | N/A | Update drug; procurement |
| 22333 | Version 7.0; 2nd February 2026 | Regimen comments; administration | Update drug; instructions, premedication |
| RM 1276 MCCR |
Version 4.0; 22nd December 2025 | Regimen comments; prophylaxis | N/A |
| 23284 | PM v5.1: 17 Jul 2025 | N/A | Update drug; instructions. |